NCT03965481Active, not recruiting
PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer
Comparing Accuracy of PET/MR vs. CECT in Assessment of Peritoneal Disease for Resectability in Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
This trial studies how well positron emission tomography/magnetic resonance (PET/MR) versus contrast enhanced computerized tomography (CECT) scans work in locating ovarian cancer tumors in patients with known or suspected ovarian cancer. PET, MR, and CECT scans use different methods to create images of areas inside the body. This trial is being done to see if PET/MR scans may help doctors locate ovarian cancer tumors, predict how well these tumors may be removed during surgery, and predict how patients respond to platinum-based chemotherapies compared to standard of care CECT scans.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 21 (actual)
- First submitted
- 24 May 2019
- Start date
- 12 May 2018
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Ovarian cancer
- NCT number
- NCT03965481
What you commit to
- Study type: Interventional
- Participants enrolled: 21
- From 12 May 2018 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients allergic to gadolinium.
- Patients with cardiac pacers.
Lab values
- Blood glucose (\> 200 mg/dl).
Other
- Patients who have eGRF \< 30.
- Pediatric patients.
- Greater than 400 pounds in weight.
- Pregnant women.
Who the study is looking for
- Patients with ovarian cancer or highly suspected ovarian cancer who are eligible to undergo laparoscopic evaluation for resectability will be enrolled in the trial.
- Patients who have estimated glomerular filtration rate (eGFR) \> 30.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.